Top

Endocrine

Published in:

01-06-2019 | Metastasis | Original Article

Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease

Authors: Chen-Tian Shen, Guo-Qiang Zhang, Zhong-Ling Qiu, Hong-Jun Song, Zhen-Kui Sun, Quan-Yong Luo

Published in: Endocrine | Issue 3/2019

Abstract

Purposess

The purpose of this study was using next-generation sequencing technique to explore the potential association between germline variants of 14 targeted genes and papillary thyroid carcinoma (PTC) predisposition as well as disease progression.

Methods

In all, 516 subjects were enrolled in this study including 416 PTC patients and 100 healthy controls. PTC patients were divided into distant metastasis group and non-distant metastasis group. Patients in distant metastasis group were further divided into radioiodine-refractory PTC (RR-PTC) and non-RR-PTC depending on their response to radioiodine therapy. Genomic DNA was extracted from peripheral blood sample and MiSeq Benchtop Sequencer was used for sequencing.

Results

We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091–3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307–71.16, p = 0.026 and 3.989/1.413–11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028–5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067–4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192–0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128–0.9076, p = 0.015 and 0.6156/0.4157–0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596–6.262).

Conclusions

Germline variants of related genes could be associated with the susceptibility of PTC as well as disease progression (distant metastasis and radioiodine-refractory status). However, these results must be further verified and the potential biological functions of these germline variants in the pathogenesis of PTC remain to be determined in future studies.

Z.L. Qiu, H.J. Song, Y.H. Xu, Q.Y. Luo, Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96(10), 3078–3086 (2011). https://doi.org/10.1210/jc.2011-0093 CrossRefPubMed

C.T. Shen, Z.L. Qiu, Q.Y. Luo, Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr. Relat. Cancer 21(2), 253–261 (2014). https://doi.org/10.1530/ERC-13-0438 CrossRefPubMed

H.J. Song, Z.L. Qiu, C.T. Shen, W.J. Wei, Q.Y. Luo, Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur. J. Endocrinol. 173(3), 399–408 (2015). https://doi.org/10.1530/EJE-15-0296 CrossRefPubMed

J. Gudmundsson, P. Sulem, D.F. Gudbjartsson, J.G. Jonasson, A. Sigurdsson, J.T. Bergthorsson, H. He, T. Blondal, F. Geller, M. Jakobsdottir, D.N. Magnusdottir, S. Matthiasdottir, S.N. Stacey, O.B. Skarphedinsson, H. Helgadottir, W. Li, R. Nagy, E. Aguillo, E. Faure, E. Prats, B. Saez, M. Martinez, G.I. Eyjolfsson, U.S. Bjornsdottir, H. Holm, K. Kristjansson, M.L. Frigge, H. Kristvinsson, J.R. Gulcher, T. Jonsson, T. Rafnar, H. Hjartarsson, J.I. Mayordomo, A. de la Chapelle, J. Hrafnkelsson, U. Thorsteinsdottir, A. Kong, K. Stefansson, Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat. Genet. 41(4), 460–464 (2009). https://doi.org/10.1038/ng.339 CrossRefPubMedPubMedCentral

M. Takahashi, V.A. Saenko, T.I. Rogounovitch, T. Kawaguchi, V.M. Drozd, H. Takigawa-Imamura, N.M. Akulevich, C. Ratanajaraya, N. Mitsutake, N. Takamura, L.I. Danilova, M.L. Lushchik, Y.E. Demidchik, S. Heath, R. Yamada, M. Lathrop, F. Matsuda, S. Yamashita, The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum. Mol. Genet. 19(12), 2516–2523 (2010). https://doi.org/10.1093/hmg/ddq123 CrossRefPubMed

J. Gudmundsson, P. Sulem, D.F. Gudbjartsson, J.G. Jonasson, G. Masson, H. He, A. Jonasdottir, A. Sigurdsson, S.N. Stacey, H. Johannsdottir, H.T. Helgadottir, W. Li, R. Nagy, M.D. Ringel, R.T. Kloos, M.C. de Visser, T.S. Plantinga, M. den Heijer, E. Aguillo, A. Panadero, E. Prats, A. Garcia-Castano, A. De Juan, F. Rivera, G.B. Walters, H. Bjarnason, L. Tryggvadottir, G.I. Eyjolfsson, U.S. Bjornsdottir, H. Holm, I. Olafsson, K. Kristjansson, H. Kristvinsson, O.T. Magnusson, G. Thorleifsson, J.R. Gulcher, A. Kong, L.A. Kiemeney, T. Jonsson, H. Hjartarson, J.I. Mayordomo, R.T. Netea-Maier, A. de la Chapelle, J. Hrafnkelsson, U. Thorsteinsdottir, T. Rafnar, K. Stefansson, Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat. Genet. 44(3), 319–322 (2012). https://doi.org/10.1038/ng.1046 CrossRefPubMedPubMedCentral

H.Y. Son, Y. Hwangbo, S.K. Yoo, S.W. Im, S.D. Yang, S.J. Kwak, M.S. Park, S.H. Kwak, S.W. Cho, J.S. Ryu, J. Kim, Y.S. Jung, T.H. Kim, S.J. Kim, K.E. Lee, D.J. Park, N.H. Cho, J. Sung, J.S. Seo, E.K. Lee, Y.J. Park, J.I. Kim, Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer. Nat. Commun. 8, 15966 (2017). https://doi.org/10.1038/ncomms15966 CrossRefPubMedPubMedCentral

Y.L. Wang, S.H. Feng, S.C. Guo, W.J. Wei, D.S. Li, Y. Wang, X. Wang, Z.Y. Wang, Y.Y. Ma, L. Jin, Q.H. Ji, J.C. Wang, Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. J. Med. Genet. 50(10), 689–695 (2013). https://doi.org/10.1136/jmedgenet-2013-101687 CrossRefPubMed

M. Matsuse, M. Takahashi, N. Mitsutake, E. Nishihara, M. Hirokawa, T. Kawaguchi, T. Rogounovitch, V. Saenko, A. Bychkov, K. Suzuki, K. Matsuo, K. Tajima, A. Miyauchi, R. Yamada, F. Matsuda, S. Yamashita, The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J. Med. Genet. 48(9), 645–648 (2011). https://doi.org/10.1136/jmedgenet-2011-100063 CrossRefPubMed

10.

S. Liyanarachchi, A. Wojcicka, W. Li, M. Czetwertynska, E. Stachlewska, R. Nagy, K. Hoag, B. Wen, R. Ploski, M.D. Ringel, I. Kozlowicz-Gudzinska, W. Gierlikowski, K. Jazdzewski, H. He, A. de la Chapelle, Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid 23(12), 1532–1540 (2013). https://doi.org/10.1089/thy.2013.0102 CrossRefPubMedPubMedCentral

11.

A.M. Jones, K.M. Howarth, L. Martin, M. Gorman, R. Mihai, L. Moss, A. Auton, C. Lemon, H. Mehanna, H. Mohan, S.E. Clarke, J. Wadsley, E. Macias, A. Coatesworth, M. Beasley, T. Roques, C. Martin, P. Ryan, G. Gerrard, D. Power, C. Bremmer, T. Consortium, I. Tomlinson, L.G. Carvajal-Carmona, Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24. J. Med. Genet. 49(3), 158–163 (2012). https://doi.org/10.1136/jmedgenet-2011-100586 CrossRefPubMed

12.

H. He, W. Li, S. Liyanarachchi, Y. Wang, L. Yu, L.K.Genutis, S. Maharry, J.E. Phay, R. Shen, P. Brock, A. de la Chapelle, The role of NRG1 in the predisposition to papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. (2017). https://doi.org/10.1210/jc.2017-01798

13.

S.K. Gara, L. Jia, M.J. Merino, S.K. Agarwal, L. Zhang, M. Cam, D. Patel, E. Kebebew, Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N. Engl. J. Med. 373(5), 448–455 (2015). https://doi.org/10.1056/NEJMoa1502449 CrossRefPubMedPubMedCentral

14.

T. Zhang, M. Xing, HABP2 G534E mutation in familial nonmedullary thyroid cancer. J. Natl. Cancer Inst. 108(6), djv415 (2016). https://doi.org/10.1093/jnci/djv415 CrossRefPubMedPubMedCentral

15.

A. Kowalik, D. Gasior-Perczak, M. Gromek, M. Siolek, A. Walczyk, I. Palyga, M. Chlopek, J. Kopczynski, R. Mezyk, A. Kowalska, S. Gozdz, The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population. Oncotarget 8(35), 58304–58308 (2017). https://doi.org/10.18632/oncotarget.16870 CrossRefPubMedPubMedCentral

16.

L.E.B. de Mello, A.N. Araujo, C.X. Alves, F.J.P. de Paiva, J. Brandao-Neto, J.M. Cerutti, The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds. Clin. Endocrinol. 87(1), 113–114 (2017). https://doi.org/10.1111/cen.13352 CrossRef

17.

C. Colombo, M. Muzza, M.C. Proverbio, G. Ercoli, M. Perrino, V. Cirello, L. Vicentini, S. Ferrero, L. Fugazzola, Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review. Clin. Endocrinol. 86(6), 837–844 (2017). https://doi.org/10.1111/cen.13316 CrossRef

18.

S. Cantara, C. Marzocchi, M.G. Castagna, F. Pacini, HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series. J. Endocrinol. Invest. 40(5), 557–560 (2017). https://doi.org/10.1007/s40618-016-0583-9 CrossRefPubMed

19.

A.L. Weeks, S.G. Wilson, L. Ward, J. Goldblatt, J. Hui, J.P. Walsh, HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer. BMC Med. Genet. 17(1), 60 (2016). https://doi.org/10.1186/s12881-016-0323-1 CrossRefPubMedPubMedCentral

20.

M. Ruiz-Ferrer, R.M. Fernandez, E. Navarro, G. Antinolo, S. Borrego, G534E variant in HABP2 and nonmedullary hyroid Cancer. Thyroid 26(7), 987–988 (2016). https://doi.org/10.1089/thy.2016.0193 CrossRefPubMedPubMedCentral

21.

A.S. Alzahrani, A.K. Murugan, E. Qasem, H. Al-Hindi, HABP2 gene mutations do not cause familial or sporadic non-medullary thyroid cancer in a highly inbred middle eastern population. Thyroid 26(5), 667–671 (2016). https://doi.org/10.1089/thy.2015.0537 CrossRefPubMed

22.

R. Sahasrabudhe, J. Stultz, J. Williamson, P. Lott, A. Estrada, M. Bohorquez, C. Palles, G. Polanco-Echeverry, E. Jaeger, L. Martin, M. Magdalena Echeverry, I. Tomlinson, L.G. Carvajal-Carmona, Tcukin: The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer. J. Clin. Endocrinol. Metab. 10(3), 1098–1103 (2016). https://doi.org/10.1210/jc.2015-3928 CrossRefPubMed

23.

Q. Zhang, F. Song, H. Zheng, X. Zhu, F. Song, X. Yao, L. Zhang, K. Chen, Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. Thyroid 23(1), 38–44 (2013). https://doi.org/10.1089/thy.2012.0228 CrossRefPubMedPubMedCentral

24.

X. Shen, G. Zhu, R. Liu, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, A.K. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, C.J. O’Neill, M.S. Sywak, R. Clifton-Bligh, B. Bendlova, V. Sykorova, M. Xing, Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer. J. Clin. Oncol. JCO2017745497 (2017). https://doi.org/10.1200/JCO.2017.74.5497

25.

M. Xing, The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clin. Endocrinol. 63(3), 263–266 (2005). https://doi.org/10.1111/j.1365-2265.2005.02332.x CrossRef

26.

H. Li, R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26(5), 589–595 (2010). https://doi.org/10.1093/bioinformatics/btp698 CrossRefPubMedPubMedCentral

27.

A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M.A. DePristo, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20(9), 1297–1303 (2010). https://doi.org/10.1101/gr.107524.110 CrossRefPubMedPubMedCentral

28.

D.C. Koboldt, Q. Zhang, D.E. Larson, D. Shen, M.D. McLellan, L. Lin, C.A. Miller, E.R. Mardis, L. Ding, R.K. Wilson, VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22(3), 568–576 (2012). https://doi.org/10.1101/gr.129684.111 CrossRefPubMedPubMedCentral

29.

K. Wang, M. Li, H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38(16), e164 (2010). https://doi.org/10.1093/nar/gkq603 CrossRefPubMedPubMedCentral

30.

I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248–249 (2010). https://doi.org/10.1038/nmeth0410-248 CrossRefPubMedPubMedCentral

31.

P.C. Ng, S. Henikoff, SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31(13), 3812–3814 (2003)CrossRefPubMedPubMedCentral

32.

J.M. Schwarz, C. Rodelsperger, M. Schuelke, D. Seelow, MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7(8), 575–576 (2010). https://doi.org/10.1038/nmeth0810-575 CrossRefPubMed

33.

S. Purcell, B. Neale, K. Todd-Brown, L. Thomas, M.A. Ferreira, D. Bender, J. Maller, P. Sklar, P.I. de Bakker, M.J. Daly, P.C. Sham, PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559–575 (2007). https://doi.org/10.1086/519795 CrossRefPubMedPubMedCentral

34.

E.Y. Zhou, Z. Lin, Y. Yang, HABP2 mutation and nonmedullary thyroid cancer. N. Engl. J. Med. 373(21), 2084–2085 (2015). https://doi.org/10.1056/NEJMc1511631#SA2 CrossRefPubMed

35.

M. Levy, H. Shapiro, C.A. Thaiss, E. Elinav, NLRP6: a multifaceted innate immune sensor. Trends Immunol. 38(4), 248–260 (2017). https://doi.org/10.1016/j.it.2017.01.001 CrossRefPubMed

36.

S. Normand, A. Delanoye-Crespin, A. Bressenot, L. Huot, T. Grandjean, L. Peyrin-Biroulet, Y. Lemoine, D. Hot, M. Chamaillard, Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl Acad. Sci. USA 108(23), 9601–9606 (2011). https://doi.org/10.1073/pnas.1100981108 CrossRefPubMedPubMedCentral

37.

H. Wang, G. Xu, Z. Huang, W. Li, H. Cai, Y. Zhang, D. Xiong, G. Liu, S. Wang, Z. Xue, Q. Luo, LRP6 targeting suppresses gastric tumorigenesis via P14(ARF)-Mdm2-P53-dependent cellular senescence. Oncotarget 8(67), 111597–111607 (2017). https://doi.org/10.18632/oncotarget.22876 CrossRefPubMedPubMedCentral

38.

M. Ge, M. Shi, C. An, W. Yang, X. Nie, J. Zhang, Z. Lv, J. Li, L. Zhou, Z. Du, M. Yang, Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma. Sci. Rep. 6, 26037 (2016). https://doi.org/10.1038/srep26037 CrossRefPubMedPubMedCentral

39.

T. Pang, M. Zhou, R. Liu, J. Luo, R. Xia, TERT rs2736098 (Ex2-659G>A) polymorphism and cancer susceptibility: evidence from a comprehensive meta-analysis. Oncotarget 8(56), 96433–96441 (2017). https://doi.org/10.18632/oncotarget.21703 CrossRefPubMedPubMedCentral

40.

G. Atzmon, M. Cho, R.M. Cawthon, T. Budagov, M. Katz, X. Yang, G. Siegel, A. Bergman, D.M. Huffman, C.B. Schechter, W.E. Wright, J.W. Shay, N. Barzilai, D.R. Govindaraju, Y. Suh, Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc. Natl Acad. Sci. USA 107(Suppl. 1), 1710–1717 (2010). https://doi.org/10.1073/pnas.0906191106 CrossRefPubMed

41.

W. Pan, L. Zhou, M. Ge, B. Zhang, X. Yang, X. Xiong, G. Fu, J. Zhang, X. Nie, H. Li, X. Tang, J. Wei, M. Shao, J. Zheng, Q. Yuan, W. Tan, C. Wu, M. Yang, D. Lin, Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum. Mol. Genet. 25(9), 1875–1884 (2016). https://doi.org/10.1093/hmg/ddw056 CrossRefPubMed

42.

Y. Qin, W. Sun, H. Zhang, P. Zhang, Z. Wang, W. Dong, L. He, T. Zhang, L. Shao, W. Zhang, C. Wu, LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer. Endocrine 59(3), 555–564 (2018). https://doi.org/10.1007/s12020-017-1520-1 CrossRefPubMed

43.

L. Ning, W. Rao, Y. Yu, X. Liu, Y. Pan, Y. Ma, R. Liu, S. Zhang, H. Sun, Q. Yu, Association between the KRAS gene polymorphisms and papillary thyroid carcinoma in a Chinese Han population. J. Cancer 7(15), 2420–2426 (2016). https://doi.org/10.7150/jca.16507 CrossRefPubMedPubMedCentral

44.

J.H. Lee, X.M. Zhao, I. Yoon, J.Y. Lee, N.H. Kwon, Y.Y. Wang, K.M. Lee, M.J. Lee, J. Kim, H.G. Moon, Y. In, J.K. Hao, K.M. Park, D.Y. Noh, W. Han, S. Kim, Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discov. 2, 16025 (2016). https://doi.org/10.1038/celldisc.2016.25 CrossRefPubMedPubMedCentral

Title: Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease
Authors: Chen-Tian Shen
Guo-Qiang Zhang
Zhong-Ling Qiu
Hong-Jun Song
Zhen-Kui Sun
Quan-Yong Luo
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Metastasis
Radioiodine Therapy
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 3/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01878-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease

Abstract

Purposess

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purposess

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Oleic acid protects insulin-secreting INS-1E cells against palmitic acid-induced lipotoxicity along with an amelioration of ER stress

The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment

Safety and efficacy of multisession gamma knife radiosurgery for residual or recurrent pituitary adenomas

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page